文献速递淋巴瘤

儿童高危霍奇金淋巴瘤AHOD0831应答指导治疗报告

Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
PubMed 文献 · Br J Haematol · 2019-06-10

AHOD0831研究针对儿童高危霍奇金淋巴瘤(IIIB/IVB期)采用基于应答的治疗策略,旨在限制累积烷化剂暴露并缩小放疗范围。快速早期应答者(RER)接受2周期ABVE-PC巩固,缓慢早期应答者(SER)接受2周期异环磷酰胺/长春瑞滨和2周期ABVE-PC,并对初始大包块和/或SER部位放疗。

要点

  • 化疗结束时持续PET阳性的11例SER患者中8例有临床活动性疾病证据。

核心结论

  • 该应答指导治疗策略未达到预设的第二次EFS目标,但EFS和OS率与近期试验结果相当,且放疗体积较历史受累野缩小。
  • 化疗结束时持续PET阳性 identifies 复发/早期进展风险特别高的人群。

研究设计与样本

  • AHOD0831研究为儿童肿瘤协作组(Children's Oncology Group)报告的针对初诊高危霍奇金淋巴瘤患儿的研究。
  • 患者为IIIB/IVB期,接受2周期ABVE-PC(多柔比星、博来霉素、长春新碱、依托泊苷、泼尼松、环磷酰胺)。
  • 快速早期应答者(RER,PET无高于纵隔血池的活性)接受2周期ABVE-PC巩固;缓慢早期应答者(SER)接受2周期异环磷酰胺/长春瑞滨和2周期ABVE-PC。
  • 对初始大包块和/或SER部位进行放疗。

主要发现

  • 11例化疗结束时持续PET阳性病灶的SER患者中,8例有临床活动性疾病证据(3例活检证实,5例疾病进展或 later 复发)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The AHOD0831 study for paediatric patients with high risk Hodgkin lymphoma tested a response-based approach designed to limit cumulative alkylator exposure and reduce radiation volumes. Patients (Stage IIIB/IVB) received two cycles of ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide). Rapid early responders [RER, no positron emission tomography (PET) activity above mediastinal blood pool] were consolidated with 2 cycles of ABVE-PC. Slow early responders (SER) received 2 cycles of ifosfamide/vinorelbine and 2 cycles of ABVE-PC. Radiotherapy was administered to sites of initial bulk and/or SER. By intent-to-treat analysis, 4-year second event-free survival (EFS; freedom from second relapse or malignancy) was 91·9% [95% confidence interval (CI): 86·1-95·3%], below the projected baseline of 95% (P = 0·038). Five-year first EFS and overall survival (OS) rates are 79·1% (95% CI: 71·5-84·8%) and 95% (95% CI: 88·8-97·8%). Eight of 11 SER patients with persistent PET positive lesions at the end of chemotherapy had clinical evidence of active disease (3 biopsy-proven, 5 with progressive disease or later relapses). Although this response-directed approach did not reach the ambitiously high pre-specified target for second EFS, EFS and OS rates are comparable with results of recent trials despite the reduction in radiotherapy volumes from historical involved fields. Persistent PET at end of chemotherapy identifies a cohort at an especially high risk for relapse/early progression.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019. PMID: 31180135. doi:10.1111/bjh.16014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。